Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity

Journal of Virology

Volumn 77, Issue 16, 2003, Pages 8843-8856

  Obuchi, Masatsugu ^a   Fernandez, Marilyn ^a   Barber, Glen N ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CONTROLLED STUDY; FIBROBLAST; GENE THERAPY; GENETIC ENGINEERING; HOST RESISTANCE; HUMAN; HUMAN CELL; LUNG METASTASIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; RNA VIRUS; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; BASE SEQUENCE; CELL LINE; CRICETINAE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-BETA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINATION, GENETIC; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 0042208208     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.16.8843-8856.2003     Document Type: Article

References (53)

1. Adkins, B., Y. Bu, and P. Guevara. 2001. The generation of Th memory in neonates versus adults: prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates. J. Immunol. 166:918-925.
2. Albini, A., C. Marchisone, F. Del Grosso, R. Benelli, L. Masiello, C. Tacchetti, M. Bono, M. Ferrantini, C. Rozera, M. Truini, F. Belardelli, L. Santi, and D. M. Noonan. 2000. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am. J. Pathol. 156:1381-1393.
3. Andreansky, S. S., B. He, G. Y. Gillespie, L. Soroceanu, J. Markert, J. Chou, B. Roizman, and R. J. Whitley. 1996. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA 93:11313-11318.
4. Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus therapy of tumors. IUBMB Life 50:1-4.
5. Balachandran, S., M. Porosnicu, and G. N. Barber. 2001. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves induction of apoptosis. J. Virol. 75:3474-3479.
6. Balachandran, S., P. C. Roberts, L. E. Brown, H. Truong, A. K. Pattnaik, D. R. Archer, and G. N. Barber. 2000. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13:129-141.
7. Barber, G. N. 2001. Host defense, viruses and apoptosis. Cell Death Differ. 8:113-126.
8. Biron, C. A. 1998. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10:383-390.
9. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
10. Cao, G., J. Su, W. Lu, F. Zhang, G. Zhao, D. Marteralli, and Z. Dong. 2001. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther. 8:497-505.
11. Chander, G., M. S. Sulkowski, M. W. Jenckes, M. S. Torbenson, H. F. Herlong, E. B. Bass, and K. A. Gebo. 2002. Treatment of chronic hepatitis C: a systematic review. Hepatology 36:S135-S144.
12. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334.
13. Darnell, J. E., Jr. 1998. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J. Interferon Cytokine Res. 18:549-554.
14. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-15628.
15. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450.
16. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
17. Ferrantini, M., and F. Belardelli. 2000. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10:145-157.
18. Fultz, P. N., and J. J. Holland. 1985. Differing responses of hamsters to infection by vesicular stomatitis virus Indiana and New Jersey serotypes. Virus Res. 3:129-140.
19. Fultz, P. N., J. A. Shadduck, C.-Y. Kang, and J. W. Strellein. 1982. Mediators of protection against lethal systemic vesicular stomatitis virus infection in hamsters: defective interfering particles, polyinosinate-polycytidylate, and interferon. Infect. Immun. 37:679-686.
20. Haque, S. J., and B. R. Williams. 1998. Signal transduction in the interferon system. Semin. Oncol. 25:14-22.
21. Hilleman, M. R. 2001. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19:1837-1848.
22. Ihle, J. N. 2001. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 13:211-217.
23. Isaacs, A., and J. Lindemann. 1957. Virus interference. 1. The interferon. Proc. Roy. Soc. Lond. B Biol. Sci. 147:258-267.
24. Kadowaki, N., S. Antonenko, J. Y. Lau, and Y. J. Liu. 2000. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J. Exp. Med. 192:219-226.
25. Kahn, J. S., A. Roberts, C. Weibel, L. Buonocore, and J. K. Rose. 2001. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75:11079-11087.
26. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189:1451-1460.
27. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92:4477-4481.
28. Lefrancois, L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J. Virol. 51:208-214.
29. Li, E., T. H. Bestor, and R. Jaenisch. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69:915-926.
30. Luft, T., K. C. Pang, E. Thomas, P. Hertzog, D. N. Hart, J. Trapani, and J. Cebon. 1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161:1947-1953.
31. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. DuBois, R. Clark, M. Aguet, and R. D. Schreiber. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442.
32. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921.
33. Naylor, S. L., A. Y. Sakaguchi, T. B. Shows, M. L. Law, D. V. Goeddel, and P. W. Gray. 1983. Human immune interferon gene is located on chromosome 12. J. Exp. Med. 157:1020-1027.
34. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286:2156-2159.
35. Odaka, M., D. H. Sterman, R. Wiewrodt, Y. Zhang, M. Kiefer, K. M. Amin, G. P. Gao, J. M. Wilson, J. Barsoum, L. R. Kaiser, and S. M. Albelda. 2001. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 61:6201-6212.
36. Rakhmilevich, A. L., K. Janssen, Z. Hao, P. M. Sondel, and N. S. Yang. 2000. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell. independent mechanism. Cancer Gene Ther. 7:826-838.
37. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
38. Schnell, M. J., L. Buonocore, E. Kretzschmar, E. Johnson, and J. K. Rose. 1996. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA 93:11359-11365.
39. Sen, G. C. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55:255-281.
40. Sotomayor, E. M., Y. X. Fu, M. Lopez-Cepero, L. Herbert, J. J. Jimenez, C. Albarracin, and D. M. Lopez. 1991. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma II. Downregulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J. Immunol. 147:2816-2823.
41. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264.
42. Steele, T. A. 2000. Recent developments in the virus therapy of cancer. Proc. Soc. Exp. Biol. Med. 223:118-127.
43. Stojdl, D. F., N. Abraham, S. Knowles, R. Marius, A. Brasey, B. D. Lichty, E. G. Brown, N. Sonenberg, and J. C. Bell. 2000. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 74:9580-9585.
44. Stojdl, D. F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, and J. C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825.
45. Thomsen, A. R., A. Nansen, C. Andersen, J. Johansen, O. Marker, and J. P. Christensen. 1997. Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int. Immunol. 9:1757-1766.
46. Toomey, N. L., V. V. Deyev, C. Wood, L. H. Boise, D. Scott, L. H. Liu, L. Cabral, E. R. Podack, G. N. Barber, and W. J. Harrington, Jr. 2001. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 20:7029-7040.
47. van den Pol, A. N., K. P. Dalton, and J. K. Rose. 2002. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76:1309-1327.
48. Vandepol, S. B., L. Lefrancois, and J. J. Holland. 1986. Sequences of the major antibody binding epitopes of the Indiana serotype of vesicular stomatitis virus. Virology 148:312-325.
49. von Hoegen, P. 1995. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol. Lett. 47:157-162.
50. Wagner, R. R., and J. K. Rose. 1996. Rhabdoviridae: the viruses and their replication, p. 1121-1135. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lipincott-Raven Publishers, Philadelphia, Pa.
51. Wang, Z. G., D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi, and P. P. Pandolfi. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:266-272.
52. Whelan, S. P., L. A. Ball, J. N. Barr, and G. T. Wertz. 1995. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA 92:8388-8392.
53. Yang, Y. L., L. F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B. R. Williams, M. Aguet, and C. Weissmann. 1995. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 14:6095-6106.